Fate Therapeutics Stock Price, News & Analysis (NASDAQ:FATE)

20 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fate Therapeutics in the last twelve months. There are currently 2 sell ratings, 13 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" FATE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in FATE, but not buy additional shares or sell existing shares.
View FATE analyst ratings or view top-rated stocks.

20 brokerages have issued 12-month price targets for Fate Therapeutics' shares. Their FATE share price targets range from $3.00 to $65.00. On average, they anticipate the company's share price to reach $10.44 in the next twelve months. This suggests a possible upside of 340.4% from the stock's current price.
View analysts price targets for FATE or view top-rated stocks among Wall Street analysts.

Fate Therapeutics' stock was trading at $10.09 at the start of the year. Since then, FATE stock has decreased by 76.5% and is now trading at $2.37.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 27th 2024.
View our FATE earnings forecast.

Fate Therapeutics, Inc. (NASDAQ:FATE) issued its quarterly earnings results on Wednesday, November, 8th. The biopharmaceutical company reported ($0.46) EPS for the quarter, beating the consensus estimate of ($0.59) by $0.13. The biopharmaceutical company earned $1.94 million during the quarter, compared to the consensus estimate of $0.99 million. Fate Therapeutics had a negative net margin of 163.04% and a negative trailing twelve-month return on equity of 38.44%.

iShares Genomics Immunology and Healthcare ETF holds 348,530 shares of FATE stock, representing 0.86% of its portfolio.

2 employees have rated Fate Therapeutics Chief Executive Officer Scott Wolchko on Glassdoor.com. Scott Wolchko has an approval rating of 100% among the company's employees. This puts Scott Wolchko in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Fate Therapeutics investors own include Cara Therapeutics (CARA), CRISPR Therapeutics (CRSP), Juno Therapeutics (JUNO), NVIDIA (NVDA), Sangamo Therapeutics (SGMO), Advanced Micro Devices (AMD), Exelixis (EXEL), Neurocrine Biosciences (NBIX), Sorrento Therapeutics (SRNE) and Gilead Sciences (GILD).

Fate Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Federated Hermes Inc. (2.49%), Jacobs Levy Equity Management Inc. (2.42%), Acadian Asset Management LLC (2.18%), Monaco Asset Management SAM (1.87%), Charles Schwab Investment Management Inc. (0.90%) and Healthcare of Ontario Pension Plan Trust Fund (0.45%). Insiders that own company stock include Bahram Valamehr, Brian T Powl, Cindy Tahl, Daniel D Shoemaker, Edward J Dulac III, J Scott Wolchko, John Mendlein, Louis T Petrillo, Mark Plavsic, Redmile Group, Llc, Shefali Agarwal, Yuan Xu and Yu-Waye Chu.
View institutional ownership trends.

Shares of FATE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.